11 news items
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AAN
AGRI
ALLG
17 Jun 24
after the company and its majority shareholder, Meridiam, announced a transaction framework agreement under which Meridiam will launch a tender offer
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
TAK
17 Jun 24
in Major Motor Drop seizure frequency compared to placebo.
In SKYLINE and SKYWAY studies, some pre-specified subgroups showed nominally
Takeda Announced Topline Data From SKYLINE And SKYWAY Phase 3 Studies Of Soticlestat (TAK-935) Plus Standard Of Care Versus Placebo Plus Standard Of Care For Refractory Dravet Syndrome, Both The Studies Missed Their Primary Endpoints
OVID
TAK
17 Jun 24
Primary Endpoint of Reduction in Major Motor Drop Seizures
Soticlestat Showed a Consistent and Favorable Safety and Tolerability Profile
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
SKYWAY Study in Lennox-Gastaut Syndrome Missed its Primary Endpoint of Reduction in Major Motor Drop Seizures
Takeda Presents Phase 2b Results for Narcolepsy Treatment at SLEEP 2024
TAK
3 Jun 24
8 weeks.
The majority of NT1 patients in the trial were found to be within normative ranges for MWT and ESS by the end of the 8
j3y2mwmyn6ebe5mg3oe6rtsctlgrhk
TAK
3 Jun 24
.
The majority of NT1 patients in the trial were found to be within normative ranges
1w6mxvo2rdqpyz2s6bfn8l5v2nev9ngo6kx7t3aagq
PFE
TAK
1 Jun 24
major categories of lymphoma: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma
ii41i z3956m2rglp14772
TAK
16 May 24
on the respective province or territory. LIVTENCITY is already covered by a majority of private insurance plans
1j33owqnh
TAK
26 Apr 24
weeks prior to major surgery. Do not administer FRUZAQLA for at least 2 weeks after major surgery and until adequate wound healing. The safety
tqbbkv i2jsigae5hhzeqob49fy2hbce44flw4lkyd91otwv
NBIX
TAK
23 Apr 24
with major
af2lnwkd1ickqhfy7p43zd5z90x2oc9sbd5nzg5xfdqzt0il01f4m
TAK
22 Apr 24
presented a major challenge when it comes to unleashing the full potential of innovative technologies and seed assets originating in Japan
- Prev
- 1
- Next